癌症以外的CAR T细胞：传染病免疫调节治疗的希望。

StephenW

Front Immunol. 2019 Nov 21;10:2711. doi: 10.3389/fimmu.2019.02711. eCollection 2019.
CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases.
Seif M1, Einsele H1, Löffler J1.
Author information

1
    Department of Internal Medicine II, University Hospital Wuerzburg, Würzburg, Germany.

Abstract

Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.

Copyright © 2019 Seif, Einsele and Löffler.
KEYWORDS:

CAR T cells; CMV; HBV; HCV; HIV; infectious diseases; invasive aspergillosis; mAb engineering

PMID:
    31824500
PMCID:
    PMC6881243
DOI:
    10.3389/fimmu.2019.02711

StephenW

前免疫。 2019十一月21; 10：2711。 doi：10.3389 / fimmu.2019.02711。 eCollection 2019。
癌症以外的CAR T细胞：传染病免疫调节治疗的希望。
Seif M1，Einsele H1，LöfflerJ1。
作者信息

1个
    德国维尔茨堡维尔茨堡大学附属医院第二内科。

抽象

传染病仍然是全世界发病率和死亡率的重要原因。尽管药物开发取得了进展，但是微生物耐药性的发生仍然是一个重要的问题。对于无反应或复发的患者，需要其他治疗策略。嵌合抗原受体（CAR）T细胞彻底改变了癌症免疫疗法，为对标准疗法无反应的患者提供了潜在的治疗选择。最近，FDA批准了两种CAR T细胞疗法，分别是Yescarta®（Kite Pharma / Gilead）和Kymriah®（Novartis），用于治疗某些类型的非霍奇金淋巴瘤和B细胞前体急性淋巴细胞白血病。过继的CAR T细胞疗法成功用于癌症，这激发了研究人员开发用于治疗传染病的CAR。在这里，我们回顾了针对病毒感染的CAR T细胞疗法的主要成就，包括人类免疫缺陷病毒，丙型肝炎病毒，乙型肝炎病毒，人类巨细胞病毒和机会性真菌感染，如侵袭性曲霉病。

版权所有©2019 Seif，Einsele和Löffler。
关键字：

CAR T细胞； CMV；乙肝病毒丙肝艾滋病毒传染性疾病;侵袭性曲霉病; mAb工程

PMID：
    31824500
PMCID：
    PMC6881243
DOI：
    10.3389 / fimmu.2019.02711

StephenW

https://www.frontiersin.org/articles/10.3389/fimmu.2019.02711/pdf